Risk factors for ocular surface squamous neoplasia recurrence following treatment with topical mitomycin C and interferon alpha-2b by Besley, Jenna et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Besley, Jenna, Pappalardo, Juanita, Lee, Graham A., Hirst, Lawrence W.,
& Vincent, Stephen J.
(2014)
Risk factors for ocular surface squamous neoplasia recurrence after treat-
ment with topical mitomycin C and interferon alpha-2b.
American Journal of Ophthalmology, 157 (2), pp. 287-293.
This file was downloaded from: http://eprints.qut.edu.au/64579/
c© Copyright 2014 Elsevier Inc.
NOTICE: this is the author’s version of a work that was accepted for publi-
cation in American Journal of Ophthalmology. Changes resulting from the
publishing process, such as peer review, editing, corrections, structural
formatting, and other quality control mechanisms may not be reflected in
this document. Changes may have been made to this work since it was
submitted for publication. A definitive version was subsequently published
in American Journal of Ophthalmology, [Volume 157, Issue 2, (February
2014)] DOI: 10.1016/j.ajo.2013.10.012
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1016/j.ajo.2013.10.012
Accepted Manuscript
Risk factors for ocular surface squamous neoplasia recurrence following treatment
with topical mitomycin C and interferon alpha-2b
Jenna Besley, Juanita Pappalardo, Graham A. Lee, Lawrence W. Hirst, Stephen J.
Vincent
PII: S0002-9394(13)00708-3
DOI: 10.1016/j.ajo.2013.10.012
Reference: AJOPHT 8713
To appear in: American Journal of Ophthalmology
Received Date: 4 September 2013
Revised Date: 18 October 2013
Accepted Date: 21 October 2013
Please cite this article as: Besley J, Pappalardo J, Lee GA, Hirst LW, Vincent SJ, Risk factors for ocular
surface squamous neoplasia recurrence following treatment with topical mitomycin C and interferon
alpha-2b, American Journal of Ophthalmology (2013), doi: 10.1016/j.ajo.2013.10.012.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Risk factors for ocular surface squamous neoplasia recurrence 
following treatment with topical mitomycin C and interferon alpha-2b. 
 
Jenna Besley1 
Juanita Pappalardo1,2 
Graham A Lee1,2,3 
Lawrence W Hirst2,4,5 
Stephen J Vincent6 
 
1City Eye Centre, Brisbane, Queensland Australia 
2University of Queensland, Brisbane, Queensland, Australia 
3Royal Brisbane Hospital, Brisbane, Queensland, Australia 
4The Australian Pterygium Centre, Brisbane, Queensland, Australia 
5Queensland Eye Institute, Brisbane, Queensland, Australia 
6School of Optometry and Vision Science, Queensland University of 
Technology 
 
Correspondence to: Associate Professor Graham A Lee, City Eye Centre, 
10/135 Wickham Tce, Brisbane, Queensland 4000, Australia. Phone: 617-
38316888.  Fax 617-38316883.  E-mail eye@cityeye.com.au 
 
Short title: Recurrence of Ocular Surface Squamous Neoplasia 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
ABSTRACT 
 
Purpose: To determine the rate of recurrence and associated risk factors following 
the use of mitomycin C (MMC) and/or interferon alpha-2b (IFN) for management of 
non-invasive ocular surface squamous neoplasia (OSSN).  
 
Design: Retrospective non-comparative interventional case series. 
 
Methods: Clinical practice setting of 135 patients treated consecutively with topical 
MMC (0.4 mg/mL) and/or IFN (1 million units/mL) for OSSN observed for clinical 
recurrence. 
 
Results: Clinical recurrences were diagnosed in 19 of 135 (14.1%) eyes following 
topical treatment.  The mean time to recurrence was 17.2 months (range 4 - 61) with 
14 (73.7%) recurring within a two year period.  There was no greater risk of 
recurrence identified for variables including lesion size, lesion location, gender, age, 
treatment type or duration.  Post-hoc log-Rank pairwise comparisons revealed that 
lesions initially treated using surgery alone had significantly reduced time to 
recurrence (21.1 ± 5.6 months) compared to previous topical treatment with MMC 
(with or without surgery) (29.6 ± 4.7 months) (p = 0.04) and primary OSSN (23.2 ± 
1.8 months) (p = 0.09). 
 
Conclusions:Topical MMC and IFN are an effective treatment modality for a wide 
range of non-invasive OSSN.  Topical therapy avoids the morbidity of excisional 
surgery with equivalent or reduced recurrence rates and should be considered as 
primary therapy. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
 
Introduction 
 
Ocular surface squamous neoplasia (OSSN) encompasses a spectrum of 
lesions arising from the squamous cells of the conjunctiva and/or cornea.1  
Excessive exposure to ultraviolet B radiation is the major etiologic factor, 
however other causes, such as human papillomavirus type 16 and 18 and HIV 
seropositivity, have also been implicated.1,2  OSSN is described as a relatively 
low-grade malignancy, as invasive disease is uncommon and tends to be 
preceded by dysplasia and carcinoma in situ.1  However, a lack of appropriate 
and effective treatment for OSSN can result in malignant change followed by 
local invasion and rarely metastasis.  Surgical excision with adequate margins 
and adjunctive cryotherapy is a well-established treatment for OSSN, 
although this is an invasive option with numerous disadvantages.   
 
Tabin et al3 described high recurrence rates following surgical excision (33% 
at 10 years despite histologically clear surgical margins).  Evidence suggests 
that the microscopic changes associated with OSSN extend beyond the 
macroscopic margin, thereby surgical excision to achieve clear margins is 
difficult.4  Techniques to examine tumor margins and conserve normal tissue 
such as Moh's micrographic surgery have been adapted for oculoplastic 
tumor work, however frozen sections are challenging to perform on small 
fragile corneal or conjunctival specimens.5  Additionally, due to the multifocal 
nature of OSSN, surgical excision results in wide collateral damage to 
adjacent areas of normal epithelium including the potential for limbal stem cell 
deficiency and visually disturbing corneal scarring.4  
 
A recent study by Galor et al examined the rates of recurrence following 
surgical excision using various techniques was 10% at 1 year, and 21% at 5 
years.6  The authors identified tarsal involvement and positive pathologic 
margins as the strongest predictors of clinical recurrence following surgical 
excision of OSSN lesions.  High grade lesions, large lesions and a previous 
patient history of OSSN were associated with an increased risk of tumor 
recurrence.  The mean time to clinical recurrence following surgical excision 
was 2.5 years.    
 
The purpose of this study was to identify predictive factors of OSSN 
recurrence following topical treatment of non-invasive OSSN, using a large 
retrospective case series.  The study examined the rates of recurrence of 
OSSN after the use of topical treatment for both primary therapy and for the 
treatment of recurrences using a combination of mitomycin C (MMC) and/or 
interferon alpha-2b (IFN).  Identification of risks for recurrence would 
potentially allow for tailored management plans, with the aim of improving 
treatment success. 
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Methods 
 
In this retrospective non-comparative interventional case series study, clinical 
data of 143 eyes of 135 patients diagnosed with OSSN were reviewed.  
Approval to conduct this study was obtained prospectively from the Royal 
Australian and New Zealand College of Ophthalmologists Human Research 
Ethics Committee (Study No 29.11).  The National Health and Medical 
Research Council guidelines were followed, and it adhered to the tenets of the 
Declaration of Helsinki. 
 
Database information allowed identification of all prescriptions for MMC or IFN 
dispensed consecutively by two oncology pharmacies - the Royal Brisbane 
and Women’s Hospital, a tertiary referral hospital in Brisbane, Queensland, 
Australia and Custom Care Compounding Pharmacy in Dural, New South 
Wales, Australia.  Eligible patients were those who had their first prescription 
dispensed between December 2001 and December 2012.  Of these patients, 
those who were under treatment by a single ophthalmologist (GAL) were 
chosen as candidates for inclusion in the study.  This was to ensure uniformity 
in treatment regimen and clinical examination techniques.  OSSN was 
diagnosed principally by clinical examination but in some equivocal cases by 
histology.  All cases were primary or recurrent non-invasive lesions.  Invasive 
lesions were excluded on the basis of tethering to the underlying sclera on 
indirect palpation of the lesion through the lid.  For those patients presenting 
with recurrent disease, previous treatment modalities were recorded.  
Treatment with MMC or IFN continued until either clinical resolution was 
achieved, or the treatment was deemed to have failed.  Treatment failure was 
defined as lack of response after 3-4 cycles of treatment with MMC and/or 
failure to achieve complete clinical resolution following up to 6 months of 
treatment with IFN.   Patients with less than 6 months follow up after clinical 
resolution were excluded from this study. 
All patients underwent a comprehensive ophthalmic examination at the 
commencement of treatment and at all follow-up visits, including uncorrected 
and corrected visual acuity, intraocular pressure measurement and slit-lamp 
examination with photography.  The diagnosis of OSSN was made by a single 
ophthalmologist experienced in examining ocular tumors (GAL).  In the 
primary cases, this was performed clinically, relying on the characteristic 
features of OSSN – gelatinous, papilliform or leukoplakic lesion with 
characteristic tufted superficial “corkscrew” vessels.  This avoided more 
invasive incisional biopsy, however in cases where the clinical diagnosis was 
uncertain, a scraping or biopsy was taken for histological diagnosis.  
Impression cytology was not available during the course of the study.  The 
location and dimensions of the lesion were recorded at the commencement of 
treatment, with appropriate measurements taken using the slit lamp.  For 
purposes of data analysis, the lesions were grouped according to the maximal 
basal diameter (in millimeters).   
 
The MMC and IFN eye drops used in this study were prepared 
extemporaneously by the oncology pharmacy of the Royal Brisbane and 
Women’s Hospital, Brisbane, Australia (2001-2010) and the Custom Care 
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Compounding Pharmacy, Sydney, Australia (2010-2012) under cytotoxic 
laminar flow conditions.  The MMC (Kyowa Kirin, Berkshire, UK) was 
prepared at a concentration of 0.04% by reconstituting 2mg powder with 5mL 
of 0.9% saline, filtered and stored in a sterile plastic bottle.  The IFN was 
prepared at a concentration of 1 million IU/mL by diluting 0.67mL of 18M 
IU/1.2mL injectable recombinant IFN α2b (Intron A) (Merck/Schering-Plough, 
UK) with 0.9% saline up to 10mL, filtered and stored in three sterile plastic 
bottles.  All side effects reported by the patients or observed during clinical 
examination were documented.  Patients were commenced on a regimen of 
MMC 0.04% qid for one week, followed by three weeks off treatment.  This 
treatment cycle was repeated until an endpoint was reached.  If necessary, 
patients were prescribed lubricant eye drops and dexamethasone 1% qid to 
resolve minor redness or irritation.  Patients were commenced on IFN 1 
million IU/mL qid if they had a previously failed treatment with MMC, or if they 
were unable to tolerate MMC as a result of side effects.  Again, this treatment 
was continued until an endpoint was reached.  Patients who failed to respond 
to topical treatment underwent surgical excision.   
 
At each follow-up visit, ophthalmic examination and data recording occurred 
as per the initial consultation.  Following commencement of treatment, 
reviews were undertaken every one to two months until clinical resolution was 
observed.  After achieving clinical resolution, patients were reviewed at 3-4 
monthly intervals for the first year, then 6 monthly for a year and then 
annually.  Episodes of recurrent disease, as indicated by evidence of active 
disease on slit-lamp examination or biopsy, were recorded and treated using 
either further topical MMC and/or IFN and/or surgical excision. 
 
Statistical analysis 
 
Univariate and multivariate Cox proportional hazard analyses were used to 
examine potential factors associated with OSSN recurrence.  In cases of 
bilateral OSSN (n = 8) only the right eye data was included to ensure 
statistical independence.  Factors included in the analyses were patient age 
and gender, history of previous OSSN treatment (none, MMC interventions, 
non-MMC interventions), lesion size (< 2 mm, 2-6 mm, > 6 mm), lesion 
location (conjunctiva, limbus, cornea), treatment type (MMC, IFN) and 
treatment duration (MMC – cycles, IFN – months).  For the multivariate 
analysis, a forward stepwise approach was employed (p < 0.05 for inclusion 
and p > 0.10 for exclusion in the model).  Kaplan-Meier (KM) analysis was 
used to examine time to OSSN recurrence and KM survival curves were 
compared using the log-Rank test.  All statistical analyses were performed 
using SPSS Version 21.0 (IBM Corp., New York, USA). 
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Results  
 
A total of 168 patients who had received treatment with MMC and/or IFN for 
OSSN were identified from the two pharmacy databases.  Of these, 143 eyes 
of 135 patients (105M:30F) were eligible for inclusion in this study.  The 
reasons for exclusion included follow-up less than 6 months (15), intolerance 
to either topical medication (6) and for adjunctive treatment in the immediate 
post-operative period following inadequate excision margin on histology (12).  
At commencement of treatment, the mean patient age was 69 years (range 
22 - 91 years).  Of the 143 eyes included, 37 (25.9%) were recurrent lesions 
following previous topical or surgical treatment by other ophthalmologists.  All 
of  these lesions as well as another 19 (13.3%) eyes were confirmed by 
histopathological examination.   
 
The 143 eyes included in the study achieved initial clinical resolution by using 
only topical agents.  Of the 129 eyes treated with MMC, clinical resolution 
occurred in 102 (79.1%) with a mean treatment of 3.3 cycles (range 2 - 6) 
(Table 1).  Fewer cycles were required if the patient had previous topical 
treatment and/or surgery.  The 27 eyes that did not resolve fully with MMC 
were given topical IFN and subsequently achieved clinical resolution with a 
mean treatment time of 3.9 months (range 1 - 8).  IFN was used as the initial 
topical treatment in 19 eyes where the patient either had a history of prior 
failed treatment with MMC (12) or a poor ocular surface prior to 
commencement of treatment (7).  Of these 19 eyes given IFN as their initial 
treatment, clinical resolution was achieved with a mean time of 5 months 
(range 2 - 8).   
 
Adverse effects occurred in 76 (58.9%) patients using MMC and in 14 (30.4%) 
patients using IFN.  The most common side effects reported were conjunctival 
hyperemia or irritation (MMC 63 (48.8%) and IFN 13 (28.2%)), followed by 
localised allergic/toxic reactions (defined as papillary conjunctivitis and/or lid 
swelling) (MMC 12 (9.3%)) and punctal stenosis (MMC 7(5.4%)).  There was 
a single case of corneal erosion in each of MMC and IFN groups. Patients 
occasionally had more than one adverse effect.  There were no cases of 
limbal stem cell deficiency identified.  The majority of side effects experienced 
were mild and tolerated by patients.  Side effects significant enough to result 
in cessation of treatment prior to clinical resolution occurred in 12 of 143 eyes 
(8.4%), all were with MMC.  However, 11 of these were subsequently 
successfully treated with topical IFN. 
 
During the follow-up period, clinical recurrences were diagnosed in 19 
(14.1%) of the 135 patients following topical treatment (Figure 1).  Of these 19 
recurrent patients, 12 (12.5%) occurred in patients with no prior treatment (n = 
96) and 7 (18.0%) occurred in those previously treated, either topically or 
surgically (n = 39).  Fourteen recurrences (15.1%) occurred in MMC only 
patients (n = 93), 4 (20.0%) occurred in MMC/IFN (n = 20) and only one 
(4.6%) occurred in INF only patients (n = 22).  The mean time to recurrence 
was 17.2 months (range 4 - 61) with 14 patients (73.7%) recurring within a 
two year period.  Table 2 summarises the results of the univariate Cox 
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proportional hazard analysis.  There was no significantly greater risk of 
recurrence associated with lesion size or location, gender, age, treatment 
duration or treatment type according to univariate Cox proportional hazard 
analysis (p > 0.05).  The only factor potentially associated with an increased 
risk of OSSN recurrence was previous treatment modality.  Lesions initially 
treated with surgical excision alone were associated with a greater risk of 
recurrence (HR 2.61, CI 0.92 - 7.43) which bordered on statistical significance 
(p = 0.07). 
 
Similarly, Kaplan-Meier analysis revealed that the variables of interest 
including lesion size and location, gender, age, treatment duration and 
treatment type did not significantly influence recurrence of OSSN (p > 0.05) 
(Table 3).  The mean time to recurrence of OSSN was 23.2 ± 1.6 months 
(Figure 2).  However, as for the univariate analysis, time to recurrence was 
influenced by previous treatment modality (Figure 3).  Post-hoc log-Rank 
pairwise comparisons revealed that lesions initially treated using surgery 
alone had significantly reduced time to recurrence (21.1 ± 5.6 months) 
compared to previous topical treatment with MMC (with or without surgery) 
(29.6 ± 4.7 months) (p = 0.04) and primary OSSN (23.2 ± 1.8 months) (p = 
0.07).  Larger lesions were associated with reduced time to recurrence (< 2 
mm 28.8 ± 4.9 months, 2 - 6 mm 23.6 ± 2.5 months, > 6 mm 21.4 ± 2.5 
months), however this trend did not reach statistical significance (p = 0.22). 
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Discussion 
 
The use of topical treatment for OSSN has been well-documented and 
confers a number of advantages when compared to surgical excision, 
including delivery of treatment to the entire ocular surface, thereby treating 
microscopic disease and subclinical dysplasia, reduced risk of stem cell 
deficiency from wide surgical excision, reduced patient morbidity, ease of 
application and cost-efficacy.4,7,8  The traditional surgical approach has 
limitations with microscopic evidence of the tumor often extending far beyond 
the macroscopic edges, and the risk of compromising the ocular surface and 
limbal stem cells, especially with large tumors and those involving the limbus.2  
Surgical excision of OSSN was generally regarded as the "gold standard" 
management in the past, as the tumor is confirmed by histopathology.  
 
There are limitations to the use of topical management.  Clinically, the 
experienced physician needs to perform a slit-lamp assessment to diagnose 
OSSN, although newer diagnostic techniques including toludine blue and 
ultra-high resolution OCT have been reported to aid in the diagnosis.9,10  If 
there is any uncertainty, impression cytology or incisional biopsy can improve 
diagnostic accuracy, however both are limited to the tissue sampled and may 
not necessarily be representative of the whole lesion.  There is also the 
potential risk of seeding neoplastic cells into deeper tissue layers with 
incisional biopsy.  It is also difficult to be certain on clinical examination alone 
regarding the depth of the lesion, however invasive disease more 
characteristically is less mobile due to involvement of the underlying sclera. It 
may be possible early malignant lesions in this series have been topically 
treated with success and no recurrence, but this is not a recommended 
practice.  It is likely malignant lesions, would fail topical treatment, resulting in 
excision and subsequent histological confirmation.   
 
In the current study, for primary OSSN lesions, topical MMC was utilized as 
first-line therapy and changed to IFN if the patient did not respond or 
experienced intolerable side-effects.  Despite the observed side-effects from 
MMC, the dosing protocol is shorter and less onerous than IFN, as well as 
being more cost effective.  Otherwise in practice, either topical agent can be 
used to commence treatment and the patient can be changed to the 
alternative agent if necessary.  The cost-benefit ratio favours this topical 
approach compared to surgical intervention that involves doctors’ fees, 
operating theatre fees and consumables, and the cost of loss of income for 
the patient during post-operative recovery. 
 
The findings from the present study suggests topical treatment is effective for 
both primary and recurrent OSSN.  A combination of MMC and IFN can be 
used, however surgical excision is still required if the lesion does not 
completely resolve.  Bahrami et al have found only one recurrence in 153 
eyes after a minimum of follow-up 12 months, using an excision with or 
without cryotherapy followed by either a course of topical 5-flurouracil 1% QID 
for two weeks or topical MMC 0.04% QID for 2-3 one-week cycles.12  Lesion 
size and location, gender, age and/or treatment duration were not identified as 
predictive factors for recurrence of OSSN following topical therapy with MMC 
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and/ or IFN in the present study.  This suggests that topical treatment can be 
utilized for presumed non-invasive OSSN lesions over a range of patient 
presentations.  The finding that recurrent OSSN following previous surgical 
excision has a tendency to increase the risk of recurrence after topical therapy 
warrants further consideration.  A possible explanation may be that surgical 
excision disrupts the natural tissue barriers to neoplastic change.  This would 
need further studies to confirm this hypothesis.  True recurrence of a lesion is 
difficult to determine with certainty as opposed to inadequate treatment with 
regrowth of residual tumor cells.  The lesions in this study were clinically 
examined to have resolved, however histological confirmation would be more 
ideal.  In practice, re-biopsy of a resolved region is not generally performed 
unless there is clinical evidence of recurrence.  The observation of a 
recurrence also depends on duration of follow-up and it is possible more 
lesions would eventually recur if followed for a longer period.  A majority 
(73.7%) of recurrences occurred within 24 months of follow-up, indicating 
follow-up should be more frequent in this period following cessation of 
treatment.   
 
Other ways to enhance topical therapy have been suggested.  Shields et al 
has reported a series of 81 tumors in 80 patients treated with topical and/or 
injection of IFN.13  They reported over 95% resolution in patients treated for 
primary, recurrent and post-surgical lesions.  Injection of the IFN (10 MIU/mlL) 
was performed by a 30-gauge needle to the sublesional and perilesional 
region, avoiding direct injection of the tumor.  This modality was not utilized in 
the current study, but would be a useful option particularly for more extensive 
lesions.  A report by Krilis et al, used topical IFN in combination with retinoic 
acid 0.01% second daily to enhance therapy by reversing the upregulation of 
matrix metalloproteinases, thereby inhibiting tumor growth and reducing rates 
of treatment failure.14  Treatment was continued for 12 months following 
resolution.  Although complete clinical resolution of 87 of 89 eyes (97.8%) was 
achieved, further study is needed to prove whether this combination and 
duration of therapy is advantageous.  Other studies have also investigated the 
use of anti-vascular endothelial growth factor agents in the treatment of 
OSSN.15  Topical 5-fluoruracil 1% has been shown to be a useful topical 
agent with a safety profile confirmed by confocal microscopy.16 
 
 
In conclusion, the findings of this study show topical therapy can be utilized as 
first-line therapy for both primary and recurrent clinically diagnosed non-
invasive OSSN.  This study suggests low rates of recurrence with topical 
therapy, comparable to surgical excision with cryotherapy, with the benefit of 
reducing the cost and risk of complications.   
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Figure Legends 
 
Figure 1.  Slitlamp photography from the right eye of an 83-year-old male.  
(Left)  Primary nasal limbal ocular surface squamous neoplasia (leukoplakic 
with corkscrew vessels) extending from 2.30 to 5.30 onto the peripheral 
cornea.  (Middle)  Appearance of nasal limbal ocular surface squamous 
neoplasia after 2 cycles of topical mitomycin-C over 2 months showing 
regression.  (Right)  Recurrence of nasal limbal ocular surface squamous 
neoplasia from 2.00 to 3.00 at 11 months following regression of the initial 
lesion. 
 
Figure 2.  Kaplan–Meier survival curve demonstrating the recurrence of ocular 
surface squamous neoplasia over time. 
 
Figure 3.  Kaplan–Meier survival curves based on previous treatment of 
ocular surface squamous neoplasia. 
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Table 1.  Average number of cycles/ months of topical mitomycin C and/or interferon 
alpha-2b to achieve clinical resolution of ocular surface squamous neoplasia.  
 
 Primary 
treatment 
Previous 
MMCa 
Previous 
surgery 
Previous 
surgery + 
MMCa 
MMCa only 
(cycles) (n = 102) 
3.3 2.5 2.7 3.0 
MMCa + IFNb 
(cycles/months) 
(n = 27) 
3.0 / 3.9 2.0 / 5.5 2.6 / 4.3 Nil 
IFNb only 
(months) (n = 19) 
5.0 4.4 6.0 3.8 
 
aMMC - mitomycin C 
bIFN - interferon alpha-2b 
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Table 2.  Univariate Cox proportional hazard analysis for ocular surface squamous 
neoplasia recurrence. 
 
Factor Descriptive (n) HRa 95% CIb P-valuec 
Age Years 1.00 0.94 - 1.04 0.70 
Gender Male (105)    
 Female (30) 1.54 0.58 - 4.08 0.38 
Previous treatment None (96)    
 MMCd (21) 0.60 0.13 - 2.70 0.51 
 Surgery alone (18) 2.61 0.92 - 7.43 0.07 
Lesion size < 2 mm (16)    
 2 - 6 mm (60) 0.40 0.11 - 1.48 0.40 
 > 6 mm (59) 0.94 0.29 - 2.99 0.94 
Lesion location Conjunctiva (6)    
 Limbus (98) 0.49 0.11 - 2.24 0.36 
 Cornea (31) 0.82 0.17 - 4.12 0.81 
Treatment MMCd (93)    
 IFNe (22) 0.27 0.04 - 2.02 0.20 
 MMCd & IFNe (20) 1.33 0.44 - 4.03 0.62 
 
Treatment duration MMCd (cycles) 0.96 0.60 - 1.52 0.85 
 IFNe (months) 0.46 0.05 - 4.33 0.50 
 
aHR – Hazard Ratio 
bCI - Confidence Interval 
cP value < 0.05 considered statistically significant 
dMMC - mitomycin C 
eIFN - interferon alpha-2b 
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Table 3.  Kaplan-Meier analysis of recurrence of ocular surface squamous neoplasia. 
 
Factor Descriptive (n) 
Mean time to 
recurrence ± 
SE (months) 
95% CI P-value (log Rank) 
All eyes (135) 23.2 ± 1.6 20.00 -26.45 NA 
Age ≤ 67 years (59) 25.8 ± 2.4 21.01 - 30.61 
 > 67 years (76) 21.2 ± 2.2 16.83 - 25.62 0.27 
Gender Male (105) 23.2 ± 1.9 19.37 - 27.05 
 Female (30) 23.3 ± 2.9 17.42 - 29.18 0.38 
Previous 
treatment  None (96) 23.2 ± 1.8 18.74 - 25.74 
 MMCd (21) 29.6 ± 4.7 19.75 - 39.39 
 Surgery alone (18) 21.1 ± 5.6 9.36 - 32.86 
0.09 
Lesion size < 2 mm (16) 28.8 ± 4.9 18.41 - 39.09 
 2 - 6 mm (60) 23.6 ± 2.5 18.68 - 28.49 
 > 6 mm (59) 21.4 ± 2.5 16.47 - 26.27 
0.22 
Lesion 
location Conjunctiva (6) 26.3 ± 2.7 19.38 - 33.28 
 Limbus (98) 23.2 ± 2.0 19.19 - 27.24 
 Cornea (31) 22.7 ± 3.1 16.43 - 28.93 
0.45 
Treatment 
type MMC
d
 (93) 22.7 ± 2.0 18.71 - 26.68 
 IFNe (22) 26.6 ± 4.2 17.92 - 35.26 
 MMCd & IFNe (20) 22.0 ± 3.8 14.16 - 9.84 
0.30 
 
 
aSE – Standard Error 
bCI - Confidence Interval 
cP value < 0.05 considered statistically significant 
dMMC - mitomycin C 
eIFN - interferon alpha-2b 
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Risk factors for ocular surface squamous neoplasia recurrence following 
treatment with topical mitomycin C and interferon alpha-2b. 
 
AJO-13-948 
 
The use of topical treatment for ocular surface squamous neoplasia confers a 
number of advantages when compared to surgical excision.  This study identifies 
predictive factors of ocular surface squamous neoplasia recurrence following topical 
treatment of non-invasive ocular surface squamous neoplasia, using a large 
retrospective case series.  Topical therapy can be utilized as first-line therapy for 
both primary and recurrent non-invasive ocular surface squamous neoplasia with low 
rates of recurrence.  
 
